/Companies

Nuntius Therapeutics

YC W21

London, GB · Founded 2021 · 2 employees · 8 known investors

Find your way into Nuntius Therapeutics

Sign up to see every warm intro you have to Nuntius Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Nuntius Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.

Founders & leadership· Y Combinator alumni (W21)

Nuntius Therapeutics was founded in 2021 by Benita Nagel and Albert Kwok.

BNBenita Nagel
Benita NagelFounder
AKAlbert Kwok
Albert KwokCo-Founder and CSOAlbert Kwok has 20+ years of experience in gene and cell therapy, vaccines, oncology, immunology, neurology, and rare and cardiometabolic diseases, and serves as a healthcare investor. He is the founder of Nuntius Therapeutics, which develops programmable nanocarriers for targeted drug delivery.

Investors · 8

Related companies · 6

NuntiusNuntius builds tools to ensure AI models comply with specified constraints and behave reliably in commercial applications.
Sixfold BioscienceSixfold Bioscience develops patented drug delivery systems for RNA therapeutics, including siRNAs for gene silencing and mRNAs for gene expression. The company works on commercialising these delivery technologies in the gene therapy and nanomedicine space.
Rejuvenation Technologies Inc.Rejuvenation Technologies develops mRNA therapeutics designed to extend healthspan by lengthening short telomeres, with preclinical results in fibrotic liver and lung disease. The company is moving toward clinical trials via IND-enabling studies and builds on a Stanford-patented platform.
NanograbNanograb develops gene therapy delivery systems using artificial intelligence to identify peptide-nanoparticle combinations that transport genetic medicines to targeted cells and tissues.
Indee LabsIndee Labs develops a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to deliver nucleic acids, proteins, and gene editing complexes into patient and donor T cells. The technology targets T cell immunotherapy discovery, development, and manufacturing.
64x Bio64x Bio develops cell-line engineering and production technologies to overcome manufacturing bottlenecks in advanced and next-generation therapies. It serves biopharma and therapeutics developers by combining large-scale parallelized screening with computational analysis to engineer high-yield cell lines.

Companies working in the same space as Nuntius Therapeutics.

Legal entities · 1

corporate structure
Nuntius Therapeutics, Inc.

Companies House · registry record

View on Companies House ↗
Registered name
NUNTIUS THERAPEUTICS LIMITED
Company number
13130725
Status
Active
Company type
Private limited company
Incorporated
13 Jan 2021
Registered office
Unit 23 The Cobalt Building, Lower Pemberton, Ashford, Kent, TN25 4BF
Nature of business (SIC)
72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Dec 2024 · next due 30 Sept 2026
Confirmation statement
last made up to 12 Jan 2026 · next due 26 Jan 2027

Current officers · 2

  • Ngai Ping Albert Kwok — director, appointed 13 Jan 2021
  • Benita Nagel — director, appointed 13 Jan 2021

Source: Companies House public register · retrieved 24 Jul 2026. Contains public sector information licensed under the Open Government Licence v3.0.

Frequently asked questions

What does Nuntius Therapeutics do?
Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.
Who founded Nuntius Therapeutics?
Nuntius Therapeutics was founded by Benita Nagel, Albert Kwok in 2021.
Who are Nuntius Therapeutics's investors?
Nuntius Therapeutics's investors include Aleka Capital, Backed, Y Combinator, Asymmetry Ventures, FoundersX, Harvard Management Company, Nadav Rosenberg, UNCOMMON DENOMINATOR.
Where is Nuntius Therapeutics headquartered?
Nuntius Therapeutics is headquartered in London, GB.